论文部分内容阅读
目的 采用放射性核素３２Ｐ治疗真性红细胞增多症（ＰＶ）的疗效、疗程、剂量及生存期等问题的探讨。方法 １３例ＰＶ患者进行３２Ｐ口服或静脉注射治疗，治疗后定期随访，确定有复发者给予下一疗程的治疗。随访时间１～１９年。结果 １３例ＰＶ病人的症状体征均有不同程度的改变，７例缓解（５３．８％），６例好转（４６％），总有效率（１００％）。生存期延长，平均１３．８年。结论 ３２Ｐ治疗ＰＶ疗效好，而且简便、安全，治疗剂量易掌握，无明显的毒副反应，导致转化成其它骨髓增生性疾患（ＭＰＤ）的风险与其自然发展过程无明显差别。一旦ＰＶ的诊断成立，建议及时地采用３２Ｐ治疗。
Objective To investigate the curative effect, course of treatment, dose and survival of radionuclide 32P in the treatment of polycythemia vera (PV). Methods Thirteen patients with PV were treated with oral administration of 32P or intravenous injection. After treatment, regular follow-up was performed to determine whether the relapse patients were given the next course of treatment. Follow-up time of 1 to 19 years. Results The symptoms and signs of 13 PV patients were changed to some extent. Among them, 7 were relieved (53.8%), 6 were improved (46%), and the total effective rate was 100%. Survival extended, with an average of 13.8 years. Conclusion 32P has a good curative effect on PV, and is simple, safe and easy to handle. There is no obvious toxic side effects and the risk of conversion to other myeloproliferative disorders (MPD) is not significantly different from its natural development. Once the PV diagnosis is established, it is recommended to promptly adopt 32P treatment.